Health Catalyst (HCAT) Stock: $35 Price Target And Outperform Rating

By Amit Chowdhry ● Mar 2, 2022
  • The shares of Health Catalyst Inc (NASDAQ: HCAT) have received a $35 price target from RBC Capital. These are the details.

The shares of Health Catalyst Inc (NASDAQ: HCAT) have received a $35 price target from RBC Capital. And RBC Capital analyst Sean Dodge is maintaining an “Outperform” rating on the shares.

Dodge adjusted the rating on the shares after its slightly better than expected results. And Dodge pointed out that Health Catalyst has made consistent steps narrowing its losses and remains on track for breakeven by 2023. Plus Dodge added that its labor-intensive PS business is still facing margin pressure due to revenue mix, wage pressures, and lower staff utilization.

Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.